	ICIVIJE DISCLOSURE FORIVI
Date	e:Aug. 18 <sup>th</sup> , 2021
	· Name:Liang Chen
	uscript Title:Pulmonary Function Changes after Thoracoscopic Lobectomy versus Intentional
Tho	acoscopic Segmentectomy for Early Stage Non-Small Cell Lung Cancer
Mar	uscript number (if known):
rela part to ti	te interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are seed to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third lies whose interests may be affected by the content of the manuscript. Disclosure represents a commitment ansparency and does not necessarily indicate a bias. If you are in doubt about whether to list a sionship/activity/interest, it is preferable that you do so.
	following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> uscript only.
to t	author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains be epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive ication, even if that medication is not mentioned in the manuscript.
	em #1 below, report all support for the work reported in this manuscript without time limit. For all other items, time frame for disclosure is the past 36 months.
	Name all entities with Specifications/Comments
	whom you have this (e.g., if payments were made to you or to your

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	X None
,	lectures, presentations,	None
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	XNone
	testimony	
7	Support for attending	XNone
	meetings and/or travel	
8	Patents planned, issued or	XNone
	pending	
9	Participation on a Data	XNone
	Safety Monitoring Board or	
1.0	Advisory Board	V. Name
10	Leadership or fiduciary role in other board, society,	XNone
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	X None
	Stock of Stock options	
12	Receipt of equipment,	XNone
	materials, drugs, medical	
	writing, gifts or other	
	services	
13	Other financial or non-	XNone
	financial interests	
ni.		audict of interest in the following bow
PIE	ase summarize the above o	onflict of interest in the following box:
	None	
	None	
_		
DIa	aco placo an "V" nove to the	a following statement to indicate your agreement:
rie	ase place all A flext to the	e following statement to indicate your agreement:
_	v lande da di	and are more than and have a fee for the control of
	x_ i certify that I have answ	vered every question and have not altered the wording of any of the questions or

Dat	e: Aug. 18 <sup>th</sup> , 2	021	
	r Name:Zhitao		
Maı	nuscript Title:	Pulmonary Function	n Changes after Thoracoscopic Lobectomy versus Intentional
	_	·	Small Cell Lung Cancer
Maı	nuscript number (if known)	):	
rela part to t	ted to the content of your ties whose interests may be	manuscript. "Related' e affected by the cont necessarily indicate a	se all relationships/activities/interests listed below that are 'means any relation with for-profit or not-for-profit third ent of the manuscript. Disclosure represents a commitment bias. If you are in doubt about whether to list a bu do so.
	following questions apply nuscript only	to the author's relation	onships/activities/interests as they relate to the <u>current</u>
to t		ension, you should de	d be <u>defined broadly</u> . For example, if your manuscript pertains clare all relationships with manufacturers of antihypertensive d in the manuscript.
	em #1 below, report all su time frame for disclosure i	s the past 36 months.  Name all entities with	•
		whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
			initial planning of the work
	All support for the present manuscript (e.g., funding, provision of study materials,	XNone	
	medical writing, article processing charges, etc.)		
	No time limit for this item.		
		Time frame:	past 36 months
	Grants or contracts from	XNone	
	any entity (if not indicated in item #1 above).		
	Royalties or licenses	XNone	

Consulting fees

\_X\_\_None

5	Payment or honoraria for	X None
,	lectures, presentations,	None
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	XNone
	testimony	
7	Support for attending	XNone
	meetings and/or travel	
8	Patents planned, issued or	XNone
	pending	
9	Participation on a Data	XNone
	Safety Monitoring Board or	
1.0	Advisory Board	V. Name
10	Leadership or fiduciary role in other board, society,	XNone
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	X None
	Stock of Stock options	
12	Receipt of equipment,	XNone
	materials, drugs, medical	
	writing, gifts or other	
	services	
13	Other financial or non-	XNone
	financial interests	
ni.		audiat of interest in the following bow
PIE	ase summarize the above o	onflict of interest in the following box:
	None	
	None	
_		
DIa	aco placo an "V" nove to the	a following statement to indicate your agreement:
rie	ase place all A flext to the	e following statement to indicate your agreement:
_	v lande da di	and are more than and have a fee for the control of
	x_ i certify that I have answ	vered every question and have not altered the wording of any of the questions or

Da	te: Aug. 18 <sup>th</sup> , 2	021		_
	ur Name:Boyu L			
Ma	nuscript Title:	Pulmonary Function Ch	anges after Thoracoscopic Lobectomy versus Intentiona	I
	-	·	ll Cell Lung Cancer	
Ma	nuscript number (if known)	:		
related to the to the to the tensor to the t	ated to the content of your ties whose interests may be transparency and does not pationship/activity/interest, of following questions apply nuscript only.	manuscript. "Related" mee affected by the content necessarily indicate a bias it is preferable that you d to the author's relationshivities/interests should beension, you should declare	ips/activities/interests as they relate to the <u>current</u> e <u>defined broadly</u> . For example, if your manuscript perta e all relationships with manufacturers of antihypertensiv	ins
	tem #1 below, report all sup time frame for disclosure i	· -	ed in this manuscript without time limit. For all other ite	ems,
		Name all entities with whom you have this	Specifications/Comments (e.g., if payments were made to you or to your	
		relationship or indicate none (add rows as needed)	institution)	
		Time frame: Since the initia	al planning of the work	
1	All support for the present	X None		
	manuscript (e.g., funding,			
	provision of study materials,			
	medical writing, article processing charges, etc.)			
	No time limit for this item.			
		Time frame: pas	t 36 months	
2	Grants or contracts from	XNone		
	any entity (if not indicated in item #1 above).			
3	Royalties or licenses	X None		
,	noyalites of ficelises	^		

Consulting fees

\_X\_\_None

5	Payment or honoraria for	X None
,	lectures, presentations,	None
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	XNone
	testimony	
7	Support for attending	XNone
	meetings and/or travel	
8	Patents planned, issued or	XNone
	pending	
9	Participation on a Data	XNone
	Safety Monitoring Board or	
1.0	Advisory Board	V. Name
10	Leadership or fiduciary role in other board, society,	XNone
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	X None
	Stock of Stock options	
12	Receipt of equipment,	XNone
	materials, drugs, medical	
	writing, gifts or other	
	services	
13	Other financial or non-	XNone
	financial interests	
ni.		audict of interest in the following bow
PIE	ase summarize the above o	onflict of interest in the following box:
	None	
	None	
_		
DIa	aco placo an "V" nove to the	a following statement to indicate your agreement:
rie	ase place all A flext to the	e following statement to indicate your agreement:
_	v lande da di	and are more than and have a fee for the control of
	x_ i certify that I have answ	vered every question and have not altered the wording of any of the questions or

Dat	te: Aug. 18 <sup>th</sup> , 2	021		
Υοι	ır Name:Weimi	in Wang		
Ma	nuscript Title:	Pulmonary Function C	hanges after Thoracoscopic Lobectomy versus Intentional	
	_	·	all Cell Lung Cancer	
Ma	nuscript number (if known)	):		
rela par to t	ated to the content of your ties whose interests may b	manuscript. "Related" me e affected by the content necessarily indicate a bia	all relationships/activities/interests listed below that are leans any relation with for-profit or not-for-profit third tof the manuscript. Disclosure represents a commitment s. If you are in doubt about whether to list a do so.	
	e following questions apply nuscript only.	to the author's relations	hips/activities/interests as they relate to the <u>current</u>	
to 1		ension, you should decla	e <u>defined broadly</u> . For example, if your manuscript pertair re all relationships with manufacturers of antihypertensiven the manuscript.	
	tem #1 below, report all su time frame for disclosure i		ted in this manuscript without time limit. For all other iter	ns,
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as		
		needed)		
		Time frame: Since the init	ial planning of the work	
-	All support for the present	XNone		
	manuscript (e.g., funding, provision of study materials,			
	medical writing, article			
	processing charges, etc.)			
	No time limit for this item.			
		Time frame: pa	st 36 months	
2	Grants or contracts from	XNone		
	any entity (if not indicated			
	in item #1 above).			
3	Royalties or licenses	XNone		

Consulting fees

X\_\_None

5	Payment or honoraria for	X None
,	lectures, presentations,	None
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	XNone
	testimony	
7	Support for attending	XNone
	meetings and/or travel	
8	Patents planned, issued or	XNone
	pending	
9	Participation on a Data	XNone
	Safety Monitoring Board or	
1.0	Advisory Board	V. Name
10	Leadership or fiduciary role in other board, society,	XNone
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	X None
	Stock of Stock options	
12	Receipt of equipment,	XNone
	materials, drugs, medical	
	writing, gifts or other	
	services	
13	Other financial or non-	XNone
	financial interests	
ni.		audict of interest in the following bow
PIE	ase summarize the above o	onflict of interest in the following box:
	None	
	None	
_		
DIa	aco placo an "V" nove to the	a following statement to indicate your agreement:
rie	ase place all A flext to the	e following statement to indicate your agreement:
_	v lande da di	and are more than and have a fee for the control of
	x_ i certify that I have answ	vered every question and have not altered the wording of any of the questions or

Da	te: Aug. 18 <sup>th</sup> , 2	.021		
	ur Name:Ning X			
			anges after Thoracoscopic Lobectomy versus Intentional	
			II Cell Lung Cancer	
rel pa to	ated to the content of your rties whose interests may b	manuscript. "Related" me e affected by the content necessarily indicate a bias	Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment . If you are in doubt about whether to list a o so.	
	e following questions apply nuscript only.	to the author's relationsh	ips/activities/interests as they relate to the <u>current</u>	
to me	the epidemiology of hypert dication, even if that medic	ension, you should declare cation is not mentioned in pport for the work reporte	edefined broadly. For example, if your manuscript pertain eall relationships with manufacturers of antihypertensive the manuscript. ed in this manuscript without time limit. For all other ite	е
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initia	al planning of the work	
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone		
		Time frame: pas	t 36 months	
	Grants or contracts from	XNone		

any entity (if not indicated

X\_\_None

\_X\_\_None

in item #1 above).

Royalties or licenses

Consulting fees

5	Payment or honoraria for	X None
,	lectures, presentations,	None
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	XNone
	testimony	
7	Support for attending	XNone
	meetings and/or travel	
8	Patents planned, issued or	XNone
	pending	
9	Participation on a Data	XNone
	Safety Monitoring Board or	
1.0	Advisory Board	V. Name
10	Leadership or fiduciary role in other board, society,	XNone
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	X None
	Stock of Stock options	
12	Receipt of equipment,	XNone
	materials, drugs, medical	
	writing, gifts or other	
	services	
13	Other financial or non-	XNone
	financial interests	
ni.		audict of interest in the following bow
PIE	ase summarize the above o	onflict of interest in the following box:
	None	
	None	
_		
DIa	aco placo an "V" nove to the	a following statement to indicate your agreement:
rie	ase place all A flext to the	e following statement to indicate your agreement:
_	v lande da di	and are more than and have a fee for the control of
	x_ i certify that I have answ	vered every question and have not altered the wording of any of the questions or

Da	te: Aug. 18 <sup>th</sup> , 2	021		_
	ur Name:Yuan L			•
Ma	nuscript Title:	Pulmonary Function Ch	anges after Thoracoscopic Lobectomy versus Intentiona	I
	-	·	ll Cell Lung Cancer	-
Ma	nuscript number (if known)	):		
rel par to	ated to the content of your rties whose interests may be transparency and does not	manuscript. "Related" me e affected by the content necessarily indicate a bias	Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment . If you are in doubt about whether to list a	
rei	ationship/activity/interest,	it is preferable that you d	o so.	
	e following questions apply nuscript only.	to the author's relationsh	ips/activities/interests as they relate to the <u>current</u>	
to		ension, you should declar	e <u>defined broadly</u> . For example, if your manuscript perta e all relationships with manufacturers of antihypertensi the manuscript.	
	tem #1 below, report all su time frame for disclosure i		ed in this manuscript without time limit. For all other it	ems,
		Name all entities with whom you have this	Specifications/Comments (e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as		
		needed)		
		Time frame: Since the initia	al planning of the work	
1	All support for the present	XNone		
	manuscript (e.g., funding,			
	provision of study materials, medical writing, article			
	processing charges, etc.)			
	No time limit for this item.			
		Time frame: pas	t 36 months	
2	Grants or contracts from	XNone		
	any entity (if not indicated			
	in item #1 above).	V N		
3	Royalties or licenses	XNone		

Consulting fees

\_X\_\_None

	Payment or honoraria for	V None	
	lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
	Payment for expert	X None	
		XNone	
	testimony		
		<u> </u>	
	Support for attending meetings and/or travel	XNone	
3	Patents planned, issued or	X None	
	pending		
)	Participation on a Data	X None	
	Safety Monitoring Board or		
	Advisory Board		
LO	Leadership or fiduciary role	X None	
_	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
l1	Stock or stock options	X None	
_	Stock of Stock options		
.2	Receipt of equipment,	X None	
	materials, drugs, medical	XNone	
	writing, gifts or other		
	services		
L3	Other financial or non-	X None	
	financial interests		
	illialiciai liiterests		
. ום	acc cummariza tha abaya a	andlist of interest in the fo	llowing hove
rie	ase summarize the above o	office of interest in the fo	nowing box.
	Nama		
	None.		
. ח	accompact on "Y" mout to the	o following statement to !:	diesta vaur agraamanti
rie	ase place an "X" next to the	e following statement to in	idicate your agreement:
>	K_ I certify that I have answ	vered every question and h	nave not altered the wording of any of the questions o

Dat	te: Aug. 18 <sup>ເກ</sup> , 2	021	
Υοι	ur Name:Chuny	u Ji	
Ma	nuscript Title:	Pulmonary Function Cha	anges after Thoracoscopic Lobectomy versus Intentional
The	oracoscopic Segmentectomy	y for Early Stage Non-Smal	l Cell Lung Cancer
Ma	nuscript number (if known)	):	
rela	ated to the content of your	manuscript. "Related" me	I relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third
to		necessarily indicate a bias.	of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a o so.
	e following questions apply nuscript only.	to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
to		ension, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.
	tem #1 below, report all su time frame for disclosure i	· ·	d in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initia	l planning of the work
L	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated in item #1 above).		
,	Royalties or licenses	X None	
,	noyalties of ficerises	^_NOTIE	

Consulting fees

X\_\_None

	Payment or honoraria for	V None	
	lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
	Payment for expert	X None	
		XNone	
	testimony		
		<u> </u>	
	Support for attending meetings and/or travel	XNone	
3	Patents planned, issued or	X None	
	pending		
)	Participation on a Data	X None	
	Safety Monitoring Board or		
	Advisory Board		
LO	Leadership or fiduciary role	X None	
_	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
l1	Stock or stock options	X None	
_	Stock of Stock options		
.2	Receipt of equipment,	X None	
	materials, drugs, medical	XNone	
	writing, gifts or other		
	services		
L3	Other financial or non-	X None	
	financial interests		
	illialiciai liiterests		
. ום	acc cummariza tha abaya a	andlist of interest in the fo	llowing hove
rie	ase summarize the above o	office of interest in the fo	nowing box.
	Nama		
	None.		
. ח	accompact on "Y" mout to the	o following statement to !:	diesta vour agraamanti
rie	ase place an "X" next to the	e following statement to in	idicate your agreement:
>	K_ I certify that I have answ	vered every question and h	nave not altered the wording of any of the questions o

Dat	e: Aug. 18 <sup>th</sup> , 2	021	
	ır Name:Wenta		
Ma	nuscript Title:	Pulmonary Function Cl	nanges after Thoracoscopic Lobectomy versus Intentional
Tho	racoscopic Segmentectom	y for Early Stage Non-Sma	all Cell Lung Cancer
Ma	nuscript number (if known)	):	
rela par to t	ated to the content of your ties whose interests may b	manuscript. "Related" m e affected by the content necessarily indicate a bia	all relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment s. If you are in doubt about whether to list a do so.
	following questions apply nuscript only.	to the author's relationsl	hips/activities/interests as they relate to the current
to t		ension, you should declar	e <u>defined broadly</u> . For example, if your manuscript pertains re all relationships with manufacturers of antihypertensive in the manuscript.
	tem #1 below, report all su time frame for disclosure i		ted in this manuscript without time limit. For all other items
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initi	ial planning of the work
-	All support for the present	XNone	
	manuscript (e.g., funding, provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: pas	st 36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	

Consulting fees

X\_\_None

5	Payment or honoraria for	X None
,	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	XNone
	testimony	
7	Support for attending	XNone
	meetings and/or travel	
8	Patents planned, issued or	XNone
	pending	
9	Participation on a Data	XNone
	Safety Monitoring Board or	
1.0	Advisory Board	V. Nov.
10	Leadership or fiduciary role in other board, society,	XNone
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	X None
	Stock of Stock options	
12	Receipt of equipment,	X None
	materials, drugs, medical	
	writing, gifts or other	
	services	
13	Other financial or non-	XNone
	financial interests	
DI.		conflict of interest in the following box:
rie	ase summanze the above t	offlict of lifterest in the following box.
	None	
Dla	assa nlaca an "Y" novt to the	e following statement to indicate your agreement:
716	ase piace all A Hext to the	s tollowing statement to indicate your agreement.
	V 1	and around a some supplier and have not altered the consulting of any of the
	$\mathtt{A}_{-}$ i certify that i have answ	vered every question and have not altered the wording of any of the questions or